Oral vaccines are potentially significant for protection against SARS CoV-2, the virus that causes COVID-19. After oral administration of the edible vaccine, the mucosal and systemic immunity responses are stimulated after antigen(s) presentation by M cells and dendritic cells. In consequence, T and B lymphocytes induce adaptive reactions that involve IgA, IgG production and recruitment of cytotoxic cells. Mucosal immunity may be the first line of defense for such infections.
Additionally, some preclinical studies based on orally administrated yeast showed that this delivery system is able to induce a protective mucosal and a systemic immune response. One vaccine is Whole-Cell Yeast-Based Vaccines, and the other vaccine is based on a yeast-derived recombinant protein comprised of the receptor binding domain (RBD) of the SARS-CoV-2.
Fig.1 Vaccines based on whole recombinant Saccharomyces cerevisiae cells
Microbiosci is a biotechnology company focusing on the microbes. Our cutting-edge technology platforms enable genome editing (knock in) and gene expression. Microbiosci is able to provide you the comprehensive service, including Pichia pastoris expression system, Saccharomyces cerevisiae expression system, S.boulardii expression system, etc. Microbiosci strive to provide complete solutions to help you every step of the way in your protein expression workflow.
The following is the details of available Yeast protein expressing strains at Microbiosci:
|SYE001||P.pastoris -SARS-CoV-2 S1(subunit 1) Protein Expression||Genome knock in|
|SYE002||P.pastoris -SARS-CoV-2 S2(subunit 2) Protein Expression||Genome knock in|
|SYE003||P.pastoris-SARS-CoV-2 RBD Expression||Genome knock in|
|SYE004||P.pastoris-SARS-CoV-2 S1(subunit 1) Protein Expression||Vector expression|
|SYE005||P.pastoris-SARS-CoV-2 S2(subunit 2) Protein Expression||Vector expression|
|SYE006||P.pastoris-SARS-CoV-2 RBD Expression||Vector expression|
|SYE007||S.cerevisiae-SARS-CoV-2 S1(subunit 1) Protein Expression||Genome knock in|
|SYE008||S.cerevisiae-SARS-CoV-2 S2(subunit 2) Protein Expression||Genome knock in|
|SYE009||S.cerevisiae-SARS-CoV-2 RBD Expression||Genome knock in|
|SYE010||S.cerevisiae-SARS-CoV-2 S1(subunit 1) Protein Expression||Vector expression|
|SYE011||S.cerevisiae-SARS-CoV-2 S2(subunit 2) Protein Expression||Vector expression|
|SYE012||S.cerevisiae-SARS-CoV-2 RBD Expression||Vector expression|
|SYE013||S.boulardii-SARS-CoV-2 S1(subunit 1) Protein Expression||Genome knock in|
|SYE014||S.boulardii-SARS-CoV-2 S2(subunit 2) Protein Expression||Genome knock in|
|SYE015||S.boulardii-SARS-CoV-2 RBD Expression||Genome knock in|
|SYE016||S.boulardii-SARS-CoV-2 S1(subunit 1) Protein Expression||Vector expression|
|SYE017||S.boulardii-SARS-CoV-2 S2(subunit 2) Protein Expression||Vector expression|
|SYE018||S.boulardii-SARS-CoV-2 RBD Expression||Vector expression|
1. Criscuolo, E. , Caputo, V. , Diotti, R. A. , Sautto, G. A. , Kirchenbaum, G. A. , & Clementi, N. . (2019). Alternative methods of vaccine delivery: an overview of edible and intradermal vaccines. Journal of Immunology Research, 2019, 1-13.
2. Andressa, A. , Higgins, J. P. , & Hodge, J. W. . (0). Vaccines based on whole recombinant saccharomyces cerevisiae cells. Fems Yeast Research(8), 8.